Tarlatamab, Tarlatamab
ETOP29-25 START-lung
Phase 2 small_molecule active
Quick answer
Tarlatamab, Tarlatamab for Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2 is a Phase 2 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Partner Therapeutics Limited
- Indication
- Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active